BioCardia enrolls first patient at Wisconsin in Phase 3 CardiAMP HF II trial

BioCardia, Inc.

First patient enrolled at University of Wisconsin School of Medicine and Public Health in Phase 3 CardiAMP HF II trial.
Trial is 250-patient randomized placebo-controlled study for ischemic HFrEF patients with elevated NTproBNP.
Dr. Amish Raval serves as national co-principal investigator; UW is a prestigious cardiology center.
Therapy uses autologous cells; cell population analysis defines doses; Helix system includes Morph DNA steerable platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.